Bristol-Myers Squibb Company (BMY) Stock: Price, Forecast & Analyst Target
Bristol-Myers Squibb Company (BMY) — MoonshotScore 85/100 (Exceptional band), calculated Nov 18, 2026. Price $58.80 (+0.79%), as of the Nov 20, 2026 trading session; market cap $120B. Expected results Feb 4, 2027.
Educational signal · not a buy or sell recommendation · How to read this
Bristol-Myers Squibb Company · BMY · NYSE · Healthcare · Drug Manufacturers - General
Research dated 2026-09-12: Bristol Myers Squibb develops, licenses and commercializes medicines across oncology, hematology, cardiovascular care, immunology and neuroscience, with Eliquis and Opdivo anchoring product revenue. Its equity story depends on whether the wider portfolio can counter the contraction embedded in longer-range revenue expectations without weakening cash generation.
Price as of Nov 20, 2026
Key Statistics
MoonshotScore v2 · Bristol-Myers Squibb Company (BMY)
ExceptionalWhy this rating? Method, drivers & history
Bands for the MoonshotScore: Exceptional 80-100 · Strong 65-79 · Fair 45-64 · Weak below 45.
- Business Quality — Is this a genuinely good business?
- Financial Safety — Could this blow up on me?
- Valuation — Am I paying a fair price?
- Growth Durability — Is the growth real and likely to last?
- Momentum — Is the market already moving on this?
Elite quality and durable growth, though the balance sheet is only middling; the market is already moving on it. Business Quality: Elite; Financial Safety: Okay; Valuation: Fair; Growth Durability: Growing; Momentum: Surging.
- EPS beat 0 of the last 4 reports
- expected results Feb 4, 2027
- Altman Z 2.67 · Piotroski F 7
Helping: business quality, durable growth, positive momentum
What has the MoonshotScore done over time?
| Recorded | Score | Band |
|---|---|---|
| 90 | Exceptional | |
| 90 | Exceptional | |
| 90 | Exceptional | |
| 85 | Exceptional | |
| 85 | Exceptional | |
| 85 | Exceptional |
Daily score refresh is delayed. This is the last recorded calculation.
Calculation uses the most recent completed US trading session. Live price changes do not update the score immediately.
Computed · How the MoonshotScore is computed →
Price & valuation
| Measure | Value | As of |
|---|---|---|
| Latest provided price | $58.80 | |
| Change on the day | +0.79% | |
| 52-week range | $45.27–$68.64 | |
| Market capitalisation | $120B | — |
| Price / earnings (trailing) | 13.57 | |
| Shares traded on the day | 12.63M | |
| Beta (volatility vs the S&P 500) | 0.23 |
Why Bristol-Myers Squibb Company scores 85
Share price, last 12 months +32.9%
$47.26 $62.80
What the price assumes
2.1% a year of free-cash-flow growth for ten years is what a $128.37B market value ( snapshot) asks for.
The price already assumes faster growth than the last 5 years delivered. Anything short of an acceleration leaves room to disappoint. It also runs ahead of the analysts' revenue path.
Reverse discounted cash flow: 10% discount rate, 3% growth after year ten, starting from trailing twelve months free cash flow of $9.29B. Inputs: FMP statements, estimates and quote.
How the stock reacts to earnings
EPS beat in 11 of the last 12 reports (2024–2026); the stock still fell the next session after 4 of those beats. Average first-session move: 4.5% either way.
- -1.4%Feb ’24
- -8.2%Apr ’24
- +8.2%Jul ’24
- +3.2%Oct ’24
- -4.8%Feb ’25
- -1.3%Apr ’25
- -3.8%Jul ’25
- +8.1%Oct ’25
- +7.6%Feb ’26
- +1.1%Apr ’26
- +3.5%Jul ’26
- +3.2%Oct ’26
Every report, with revenue and five-session moves
| Report | EPS | Revenue | Next session | 5 sessions |
|---|---|---|---|---|
| Beat | Beat | +3.2% | +4.2% | |
| Beat | Beat | +3.5% | +1.7% | |
| Beat | Beat | +1.1% | -2.3% | |
| Beat | Beat | +7.6% | +3.9% | |
| Beat | Beat | +8.1% | +9.5% | |
| Beat | Beat | -3.8% | -1.3% | |
| Beat | Beat | -1.3% | +2.2% | |
| Beat | Beat | -4.8% | -6.3% | |
| Beat | Beat | +3.2% | +3.9% | |
| Beat | Beat | +8.2% | +7.7% | |
| In line | Beat | -8.2% | -10.6% | |
| Beat | Beat | -1.4% | +2.3% |
Beats have usually been rewarded — 7 of 11 drew a higher close the next session.
What management is saying differently
Management's own words on the Q3 FY2026 call () against Q2 FY2026 (). Analysts' questions are left out.
- New this call: “long term”, “late stage”, “stage pipeline”, “christopher boerner” — none of them came up in Q2 FY2026.
- Gone quiet: “phase iii”, “long-term growth”, “financial flexibility”, “forward-looking statements” — regular themes last call, absent this time.
The tone held steady from one call to the next; what changed is the subject matter, not the confidence.
Our track record on this stock
Since the score went from 89 to 85 while the share price moved -12.6% through .
The score has stayed in the Exceptional band across the stretch we have recorded; we grade each band change three months after it happens.
The crowd against our signals
- Analysts: 45% of 42 rate it a buy; the average target sits +12.4% from the price of $58.80.
- Last 90 days: 0 upgrades and 1 downgrade among 8 rating actions.
- Our signals: Exceptional band; strongest pillar Business Quality (92), weakest Financial Safety (50).
Our signals are more constructive than the crowd, led by Business Quality.
Price & events
Triangles mark reported quarters on the line: pointing up is above the recorded estimate, down is below, a diamond means no estimate on file. Numbers key to the dated list. Point at or tab to any week for its close.
Events behind the price
- · Earnings results · above the recorded estimate
- · Earnings results · above the recorded estimate
- · Earnings results · above the recorded estimate
- · Earnings results · above the recorded estimate
Results dates follow the earnings feed; call dates follow the transcript provider. Nearby dates do not establish that an event caused a price move.
Upcoming events
How to read these dates
Estimated dates can change.
Other perspectives
Council score for Bristol-Myers Squibb Company (BMY): perspectives
Some lenses disagree with the MoonshotScore. Compare their readings below; each uses a different method.
5-Factor Breakdown
Legends Council
5 lenses, 5 current
AI simulations built from the named investors' published principles. Not affiliated with, endorsed by, or the opinion of these individuals. How these lenses are built
Read on: Nov 20, 2026
Munger's Mindset
Balance Sheet & Valuation
Read on: Nov 21, 2026
How to read these bars and different assessments
Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.
Bars show each model's ordered assessment on its own scale, not a probability or a comparable investment return. The adjacent words give the assessment; more filled segments indicate a stronger model reading.
One of these lenses reads this company less favourably than the MoonshotScore does: Englander-style lens. Each lens is a separate scoring function over its own inputs, so a disagreement is a difference of method rather than a correction — the page's answer stays the MoonshotScore above.
The Munger lens reads the current price as undervalued against its own estimate of value.
Readings on this page are from Nov 21, 2026, except a card that shows its own read date.
What is Bristol-Myers Squibb Company (BMY), and what does it report?
Short answer · as of
Bristol Myers Squibb sells medicines rather than generalized healthcare services.
Research dated 2026-09-12.
Demand comes from the use of therapies such as Eliquis for clot and stroke prevention, Opdivo and Yervoy for cancer, Orencia for inflammatory disease, and Breyanzi for eligible lymphoma patients; distribution runs through wholesalers, pharmacies, hospitals, clinics and government organizations.
Reported revenue therefore measures a commercial drug portfolio with sharply different indications and treatment settings. Eliquis and Opdivo dominate the disclosed product view, while Orencia, Revlimid and Yervoy contribute smaller streams, so consolidated growth can conceal meaningful changes in the product mix.
What do the latest results show for Bristol-Myers Squibb Company (BMY)?
Research dated 2026-09-12.
Revenue rebounded in the latest period and exceeded the recent range. Gross profit, operating income and net income rose more sharply than sales, while research spending also increased, showing stronger profit conversion without a retreat from development expense.
The earnings history shows an uninterrupted run of revenue and earnings results above consensus. That is an expectations observation rather than evidence of smooth underlying growth: annual revenue recently changed little while net income swung from a large loss to a substantial profit, and quarterly cash generation has remained uneven.
Where is operating spending going?
Revenue alongside research and development, selling, general and administrative expenses, and the FMP standardized operating result.
| Period end | Revenue | R&D | SG&A | FMP standardized operating result |
|---|---|---|---|---|
| Sep 30, 2026 | Not available | Not available | Not available | Not available |
| Jun 30, 2026 | Not available | Not available | Not available | Not available |
| Mar 31, 2026 | Not available | Not available | Not available | Not available |
| Dec 31, 2025 | Not available | Not available | Not available | Not available |
How to read these figures
Amounts are in US dollars. The operating result is Financial Modeling Prep’s standardized figure, so it can differ from the operating line in the company’s filing. It is not net income or cash flow.
Did results meet expectations?
Reported earnings and revenue alongside the estimates recorded by the provider.
- Latest report · revenue
- $13.07B Oct 29, 2026
- Latest report · revenue estimate
- $12.72B Oct 29, 2026
- Latest report · revenue vs estimate
- Above estimate Oct 29, 2026
- Latest report · EPS vs estimate
- Above estimate Oct 29, 2026
| Report date | Revenue · reported | Revenue · estimate | EPS · reported | EPS · estimate |
|---|---|---|---|---|
| Oct 29, 2026 | $13.07B | $12.72B | $1.3500 | $1.1000 |
| Jul 30, 2026 | $12.97B | $11.74B | $2.0400 | $1.6000 |
| Apr 30, 2026 | $11.49B | $10.93B | $1.5800 | $1.4200 |
| Feb 5, 2026 | $12.50B | $12.28B | $1.2600 | $1.2300 |
How to read these figures
Dates are when results were reported, not quarter ends. Amounts are in US dollars; EPS is per share. The source does not say whether EPS is basic, diluted or adjusted, so it can differ from the EPS in the income statement.
Quarterly income statement — 4 quarters
| Period | Revenue | Net income | EPS |
|---|---|---|---|
| Sep 2025 | $12.22B | $2.20B | $1.08 (diluted) |
| Q4 FY2025 | $12.50B | $1.09B | $0.53 (diluted) |
| Q1 FY2026 | $11.49B | $2.68B | $1.31 (diluted) |
| Q2 FY2026 | $12.97B | $3.32B | $1.62 (diluted) |
What are the financial strengths and risks for Bristol-Myers Squibb Company (BMY)?
Short answer
Cash and short-term investments were $0.00 at the Sep 30, 2026 balance-sheet date. This figure does not establish a cash runway.
Research dated 2026-09-12.
Operations have generated positive cash throughout the reported quarterly series, with capital spending consuming a modest share of that inflow. Short-term liquidity covers near-term obligations, and the latest cash balance improved from the prior period.
Debt remains far above cash and investments, leaving Bristol Myers Squibb in a substantial net-debt position. The company-specific vulnerability is that Eliquis and Opdivo carry much of the disclosed product base; erosion in those franchises would have to be absorbed by other medicines while research spending and debt claims continue. Longer-range revenue estimates indicate that this replacement burden is already central to market expectations.
What should you watch next at Bristol-Myers Squibb Company (BMY)?
Short answer · as of
The next earnings report is expected on Feb 4, 2027.
Research dated 2026-09-12.
At the scheduled earnings release, watch whether revenue remains near its latest high, whether gross profit continues to translate into operating income, and whether reported revenue and earnings again clear consensus. Research spending also deserves attention because the latest advance in profitability occurred alongside a higher development outlay.
Beyond the headline result, the useful test is product substitution: gains outside Eliquis and Opdivo need to become large enough to change the declining path embedded in longer-range estimates. Cash conversion should confirm the accounting result, while movement in cash relative to debt will show whether operating strength is improving financial flexibility.
What the records here don't tell us
- No forward revenue or earnings estimate is on file.
Checked against the records this page reads, on the dates shown above.
How does Bristol-Myers Squibb Company compare with its peers?
Short answer
Bristol-Myers Squibb Company's score ranks tied for 4th of 13 in the bounded comparison shown, against 12 same-model peers. These are company scores, not expected investment returns. The set lists named competitors first, then companies in the same data-provider industry classification closest in market value; that classification is the provider's, not our judgment of business similarity.
Research dated 2026-09-12.
Bristol Myers Squibb belongs with commercial biopharmaceutical portfolios rather than businesses valued mainly on research prospects. Its mix combines a major anticoagulant franchise, broad oncology medicines, immunology and hematology products, and an autologous cell therapy, supported by established revenue and operating cash flow.
Therapeutic breadth does not produce balanced economics. Eliquis and Opdivo still dominate disclosed product revenue, making Bristol Myers Squibb less a collection of equally weighted franchises than a mature commercial base funding the search for its eventual replacements.
| Company | Price | Market value | Score |
|---|---|---|---|
| $1351.12 Nov 19, 2026 | $1.20T | 98 5-pillar Nov 18, 2026 | |
| $520.66 Nov 19, 2026 | $132B | 90 5-pillar Nov 18, 2026 | |
| $46.06 Nov 19, 2026 | $111B | 87 5-pillar Nov 18, 2026 | |
| Bristol-Myers Squibb Company (BMY) — this page | $58.80 | $120B | 85 |
| $174.35 Nov 20, 2026 | $270B | 85 5-pillar Nov 18, 2026 | |
| $438.82 Nov 19, 2026 | $237B | 84 5-pillar Nov 18, 2026 | |
| $283.54 Nov 19, 2026 | $501B | 83 5-pillar Nov 18, 2026 | |
| $267.14 Nov 19, 2026 | $643B | 83 5-pillar Nov 18, 2026 | |
| $151.22 Nov 19, 2026 | $286B | 82 5-pillar Nov 18, 2026 | |
| $80.84 Nov 20, 2026 | $103B | 81 5-pillar Nov 18, 2026 | |
| $47.76 Nov 20, 2026 | $95.7B | 77 5-pillar Nov 18, 2026 | |
| $166.53 Nov 19, 2026 | $207B | 72 5-pillar Nov 18, 2026 | |
| $132.81 Nov 19, 2026 | $327B | 69 5-pillar Nov 18, 2026 |
Only 5-pillar scores are ranked together. Other models are not directly comparable. Price and score dates are shown separately; market-value dates are unavailable.
The records behind this page
Analyst targets & estimates
What analysts have on file
- Price target, low to high
- $41.00 – $78.00
- Consensus target
- $66.14
- Median target
- $66.00
Consensus record · Captured .
Measured against a quoted price of $58.80 (as of Nov 20, 2026).
Insider activity
Form 4 records via FMP · Of the newest 100 records, those within the last 180 days, newest dated Nov 5, 2026
- Transactions
- 43
- Identified insiders
- 14
- Purchases
- 0
- Sales
- 3
- Other transactions
- 40
Purchases and sales use the reported transaction category. Other transactions include awards, exercises, gifts, withholding and unclassified activity; an acquisition or disposition alone is not a purchase or sale. These records do not establish intent.
Who holds the shares?
Institutional ownership reported through 13F filings.
Tracked investors
Which of the 16 named investors we follow held BMY in their latest 13F filing, and what they did against the filing before it.
None of the 16 tracked investors reported BMY in their latest 13F filing.
How to read these figures
These filings arrive after the quarter ends. Names appear as the provider lists them, not as a verified ranking, and without filing dates. Related managers can appear separately, so their shares are not added together. Tracked investors: each fund's own latest 13F, so funds that have not filed the newest quarter yet show their previous one; weight is the share of the fund's reported 13F value.
What has been published about Bristol-Myers Squibb Company (BMY)?
Common Questions About BMY (Healthcare)
Research dated 2026-09-12; the full attribution is under Sources. The last 2 questions are answered from this page's own dated data, not from the research.
How dependent is Bristol Myers Squibb on Eliquis and Opdivo?
Eliquis and Opdivo are the dominant disclosed product revenue streams. Their scale gives Bristol Myers Squibb a large commercial base, but it also means weakness in either franchise would require meaningful offsets from the rest of the portfolio.
Can Breyanzi change Bristol Myers Squibb's business mix?
Breyanzi gives Bristol Myers Squibb exposure to autologous cell therapy for eligible lymphoma patients. The disclosed revenue mix remains led by Eliquis and Opdivo, so a broader economic shift would require specialty therapies such as Breyanzi to become much more consequential within the portfolio.
Why do Bristol Myers Squibb earnings move more than revenue?
Annual revenue recently remained nearly level while net income moved from a large loss to a substantial profit, and quarterly profit has also fluctuated more than sales. Research and commercial spending are large enough that changes below the revenue line can materially alter reported earnings.
What would improve Bristol Myers Squibb's declining revenue outlook?
Sustained growth from medicines outside Eliquis and Opdivo would need to offset pressure on the leading franchises. Confirmation would appear as a less concentrated product mix, resilient consolidated sales and continued cash generation despite ongoing research spending.
What is the BMY stock price today?
The last price recorded for Bristol-Myers Squibb Company (BMY), with its trading session and source, is listed under Price & valuation on this page. It is a provider snapshot, not a live exchange feed, so check a brokerage quote before you trade.
What is the BMY price target?
The analyst consensus price target for Bristol-Myers Squibb Company (BMY), with its range and the date it was captured from FMP, is listed under Analyst targets & estimates on this page. Targets are analyst opinions and change often; they are not a Stock Expert AI forecast.
Research written by Codex (gpt-5.6-sol) on 2026-09-12. AI-authored analysis; source dates are listed under Sources. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief.
Sources: the source register lists the 42 figures on this page — 1 from SEC filings and earnings calls, 35 from Financial Modeling Prep (FMP), 3 with no recorded source, 2 computed by us, formula shown in the register and 1 from Stock Expert AI's own score and rank. Its rows (value as shown, as-of date, tier and source link) are in the Markdown version of this page.
Publication details and research sources
- Published
- Research standards
- Methodology · Editorial policy · Corrections
- Report a number
- sedat@stockexpertai.com
Sources (as of 2026-09-12), by section of the research
ETFs that hold BMY
Funds in our ETF coverage that list BMY among the top 10 holdings on their fund page, largest weight first. Each weight is the fund's reported holding weight as of the date in its row.
| ETF | Weight | Holdings as of |
|---|---|---|
| iShares Evolved U.S. Innovative Healthcare ETF (IEIH) | 5.36% | |
| Brookstone Value Stock ETF (BAMV) | 4.41% | |
| Alger Russell Innovation ETF (INVN) | 2.71% | |
| WisdomTree U.S. High Dividend Fund (DHS) | 2.51% | |
| Pacer US Cash Cows 100 ETF (COWZ) | 2.21% | |
| SPDV ETF | 2.05% | |
| UVA Dividend Value ETF (UVDV) | 1.72% |
